⌕
Arcutis Biotherapeutics · ARQT · Nasdaq
Tenet 43 · Weak
Compare
$27.33+0.66%At closeTenet 43 · Weak
$27.33+0.18 (+0.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arcutis Biotherapeutics (ARQT) Institutional Ownership

13F filers reported holding 19.0% of Arcutis Biotherapeutics (ARQT) shares as of Sep 30, 2026, across 144 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
19.0%
Sep 30, 2026
13F filers
144
quarter ended Sep 30, 2026
13F value
$634.1M
24.0M shares
Quarter's fund flow
Mild accumulation
40 new · 11 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (40 new · 58 increased · 23 reduced · 11 closed · 12 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 144 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 4, 2026Matsuda MasaruEVP, Chief Legal OfficerAcquired · Option exercise40,000$3.64↗
Nov 4, 2026Matsuda MasaruEVP, Chief Legal OfficerDisposed · Open-market sale40,000$34.32↗
Nov 4, 2026Matsuda MasaruEVP, Chief Legal OfficerDisposed · Option exercise40,000Stock Option (right to buy)—↗
Nov 2, 2026Matsuda MasaruEVP, Chief Legal OfficerDisposed · Open-market sale1,219$31.86↗
Nov 2, 2026Burnett PatrickEVP, Chief Medical OfficerDisposed · Open-market sale943$31.86↗
Nov 2, 2026Watanabe Todd FranklinSee RemarksDisposed · Open-market sale4,377$31.86↗
Oct 23, 2026SCOTT ROBERT AdirectorAcquired · Grant / award2,819—↗
Oct 23, 2026SCOTT ROBERT AdirectorAcquired · Grant / award20,507Stock Option (right to buy)—↗
Oct 23, 2026SCOTT ROBERT AdirectorAcquired · Grant / award8,663Stock Option (right to buy)—↗
Oct 15, 2026Welgus Howard G.directorAcquired · Option exercise822$6.52↗
Oct 15, 2026Welgus Howard G.directorAcquired · Option exercise1,018$7.51↗
Oct 15, 2026Welgus Howard G.directorAcquired · Option exercise2,254$8.63↗
Oct 15, 2026Welgus Howard G.directorDisposed · Open-market sale4,728$26.93↗
Oct 15, 2026Welgus Howard G.directorDisposed · Option exercise822Stock Option (right to buy)—↗
Oct 15, 2026Welgus Howard G.directorDisposed · Option exercise1,018Stock Option (right to buy)—↗
Oct 15, 2026Welgus Howard G.directorDisposed · Option exercise2,254Stock Option (right to buy)—↗
Sep 16, 2026Matsuda MasaruSee RemarksDisposed · Open-market sale3,674$25.00↗
Sep 15, 2026Welgus Howard G.directorAcquired · Option exercise822$6.52↗
Sep 15, 2026Welgus Howard G.directorAcquired · Option exercise1,019$7.51↗
Sep 15, 2026Welgus Howard G.directorAcquired · Option exercise2,255$8.63↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Arcutis Biotherapeutics do institutions hold?

13F filers reported holding 19.0% of Arcutis Biotherapeutics' shares as of Sep 30, 2026, across 144 filers.

How many 13F filers hold Arcutis Biotherapeutics?

Arcutis Biotherapeutics was held by 144 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.